신경 진단 시장 : 제품, 적응증, 최종사용자별 - 세계 예측(2025-2030년)

The Neurodiagnostics Market was valued at USD 7.34 billion in 2023, expected to reach USD 7.97 billion in 2024, and is projected to grow at a CAGR of 8.71%, to USD 13.18 billion by 2030.

The neurodiagnostics market entails the development and utilization of diagnostic tools and tests to assess and monitor neurological disorders. As the prevalence of neurological conditions like Alzheimer's, epilepsy, and Parkinson's disease continues to rise, the need for precise diagnostic modalities intensifies. The market encompasses various applications such as neuroimaging, in-vitro diagnostics, and neuro-informatics, catering to healthcare facilities, diagnostic laboratories, and academic research centers. Key growth drivers include the increasing geriatric population, advancements in neuroimaging technologies, and heightened demand for minimally invasive diagnostics. Innovations in AI-driven imaging analysis and portable EEG devices present promising opportunities for industry players. Personalized medicine, driven by deeper genetic insights and biomarker identification, is opening up new avenues for tailored treatments, advancing both patient outcomes and market expansion.

Challenges within the neurodiagnostics market include high costs associated with cutting-edge imaging equipment and a scarcity of skilled professionals. Regulatory hurdles and the complexity of neurological disorders often delay product development and approval processes, posing further barriers. To overcome these challenges, businesses should focus on developing cost-effective diagnostic tools and investing in training programs to bridge the expertise gap. Collaborative research with academic institutions could also expedite the discovery of novel biomarkers and therapeutics, enhancing market growth. Areas ripe for innovation include real-time monitoring solutions and the integration of digital health technologies, which can facilitate early diagnosis and remote monitoring, particularly valuable in telemedicine settings.

Despite some hurdles, the continuous growth in healthcare expenditure, coupled with increased patient awareness, suggests a promising outlook for the neurodiagnostics market. It remains pivotal for companies to stay ahead by leveraging big data analytics and machine learning to refine diagnostic accuracy and patient stratification. Expanding reach in emerging markets, where neurological disorders are underdiagnosed, could further bolster growth. Thus, strategic partnerships and investments in R&D are critical to harness the full potential of neurodiagnostics innovations, ensuring companies remain competitive and effective in addressing the evolving global demands for neurological healthcare solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neurodiagnostics Market

The Neurodiagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidences of neurological disorders worldwide
  • Growing awareness among patients for early disease diagnosis for effective treatment
  • Growing adoption of innovative diagnostic technologies
• Market Restraints
  • High cost associated with the neurodiagnostic devices
• Market Opportunities
  • Advances in genomics and proteomics for neurodegenerative disorders diagnosis
  • Ongoing clinical trials for neurological disease
• Market Challenges
  • Limited availability of skilled healthcare professionals

Porter's Five Forces: A Strategic Tool for Navigating the Neurodiagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neurodiagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neurodiagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neurodiagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neurodiagnostics Market

A detailed market share analysis in the Neurodiagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neurodiagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neurodiagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neurodiagnostics Market

A strategic analysis of the Neurodiagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neurodiagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc., Adeor Medical AG, Advanced Brain Monitoring, Inc., Canon Medical Systems USA, Inc., DEYMED Diagnostic s.r.o., F. Hoffmann-La Roche Ltd., GE Healthcare, Koninklijke Philips N.V., Lifelines Neuro Company, LLC, Medtronic PLC, Mitsar Co., Ltd., Natus Medical Incorporated, Nihon Kohden Corporation, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Neurodiagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Clinical Testing Instrument, Diagnostic & Imaging System, and Reagent & Consumable. The Clinical Testing Instrument is further studied across NGS Instrument, PCR Instrument, and Sanger Sequencer. The Diagnostic & Imaging System is further studied across Angiography System, CT Scanner, EEG System, EMG Device, MEG Device, MRI System, PET Scanner, and Ultrasound Imaging System. The Reagent & Consumable is further studied across Antibody, Buffer, Enzyme, Protein, & Peptide, Media & Sera, Probe, and Solvent.
• Based on Indication, market is studied across Epilepsy, Headache Disorder, Neurodegenerative Diseases, Sleep Disorder, and Stroke.
• Based on End User, market is studied across Ambulatory Care Center, Diagnostic Laboratory & Imaging Center, Hospital & Clinic, and Neurology Center.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidences of neurological disorders worldwide
    • 5.1.1.2. Growing awareness among patients for early disease diagnosis for effective treatment
    • 5.1.1.3. Growing adoption of innovative diagnostic technologies
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with the neurodiagnostic devices
  • 5.1.3. Opportunities
    • 5.1.3.1. Advances in genomics and proteomics for neurodegenerative disorders diagnosis
    • 5.1.3.2. Ongoing clinical trials for neurological disease
  • 5.1.4. Challenges
    • 5.1.4.1. Limited availability of skilled healthcare professionals
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Neurodiagnostics Market, by Product

• 6.1. Introduction
• 6.2. Clinical Testing Instrument
  • 6.2.1. NGS Instrument
  • 6.2.2. PCR Instrument
  • 6.2.3. Sanger Sequencer
• 6.3. Diagnostic & Imaging System
  • 6.3.1. Angiography System
  • 6.3.2. CT Scanner
  • 6.3.3. EEG System
  • 6.3.4. EMG Device
  • 6.3.5. MEG Device
  • 6.3.6. MRI System
  • 6.3.7. PET Scanner
  • 6.3.8. Ultrasound Imaging System
• 6.4. Reagent & Consumable
  • 6.4.1. Antibody
  • 6.4.2. Buffer
  • 6.4.3. Enzyme, Protein, & Peptide
  • 6.4.4. Media & Sera
  • 6.4.5. Probe
  • 6.4.6. Solvent

7. Neurodiagnostics Market, by Indication

• 7.1. Introduction
• 7.2. Epilepsy
• 7.3. Headache Disorder
• 7.4. Neurodegenerative Diseases
• 7.5. Sleep Disorder
• 7.6. Stroke

8. Neurodiagnostics Market, by End User

• 8.1. Introduction
• 8.2. Ambulatory Care Center
• 8.3. Diagnostic Laboratory & Imaging Center
• 8.4. Hospital & Clinic
• 8.5. Neurology Center

9. Americas Neurodiagnostics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Neurodiagnostics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Neurodiagnostics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories Inc.
• 2. Adeor Medical AG
• 3. Advanced Brain Monitoring, Inc.
• 4. Canon Medical Systems USA, Inc.
• 5. DEYMED Diagnostic s.r.o.
• 6. F. Hoffmann-La Roche Ltd.
• 7. GE Healthcare
• 8. Koninklijke Philips N.V.
• 9. Lifelines Neuro Company, LLC
• 10. Medtronic PLC
• 11. Mitsar Co., Ltd.
• 12. Natus Medical Incorporated
• 13. Nihon Kohden Corporation
• 14. Siemens Healthineers AG
• 15. Thermo Fisher Scientific, Inc.